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This article presents unrevealed details of the systematic review
process of the article “The number of FoxP3 regulatory T cells in
the circulation may be a predictive biomarker for kidney trans-
plant recipients: A multistage systematic review” (Herrera-Gómez
et al., 2018). Eligibility criteria guiding searches and study selec-
tion, the risk of bias assessment, the assessment of medicine-testvier Inc. This is an open access article under the CC BY license
.intimp.2018.10.028
gy and Therapeutics, Faculty of Medicine, University of Valladolid, Avenida
4983423022.
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F. Herrera-Gómez et al. / Data in Brief 21 (2018) 2567–25752568codependency (evaluation of the body of evidence), and meta-
analytic calculations are provided. The data allows other
researchers, particularly those involved in experiments on Trans-
lational Epidemiology applied to Pharmacology, to corroborate and
extend our assessments.
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology
ore speciﬁc subject area Translational pharmacology
ype of data Text, tables, and ﬁgures.
ow data was acquired Deﬁnition of eligibility criteria and search strategy for study selec-
tion, risk of bias assessment, assessment of codependent health
technologies, and meta-analytic assessment.ata Format Raw and analyzed.
xperimental factors Systematic review protocol registration, study selection process
(against eligibility criteria), and data extraction.
xperimental features Inclusion and exclusion criteria, full search strategy, risk of bias
assessment, assessment of medicine–test codependency, and con-
tinuous data meta-analysis.ata source location Valladolid, Spain, 41.654444°, 4.7175°
ata accessibility Data is with this article.
elated research article F. Herrera-Gómez, W. del Aguila, A. Tejero-Pedregosa, M. Adler, R.
Padilla-Berdugo, A. Maurtua-Briseño-Meiggs, Julio Pascual, Manuel
Pascual, David San Segundo, Sebastiaan Heidt, Javier Álvarez, Carlos
Ochoa-Sangrador, Claude Lambert, The Number of FoxP3 Regulatory
T Cells in The Circulation May Be a Predictive Biomarker for Kidney
Transplant Recipients: A Multistage Systematic Review, Int. Immu-
nopharmacol. 65 (2018) 483–492 [1]Value of the data
 In the ﬁeld of Translational Pharmacology, sharing systematic review process details is very
important.
 This data allows other researchers to corroborate and extend our assessments.
 The main aim of sharing this data is to improve the qualiﬁcation of potential predictive biomarkers.1. Data
In addition to links to the four systematic review protocols registered in the International Pro-
spective Register of Systematic Reviews (PROSPERO) (Appendix A. Supplementary material. Text S1),
this article presents the inclusion and exclusion criteria ( Tables 1 and 2), the entire search strategy for
the systematic reviews performed (Appendix A. Supplementary material. Text S2), the risk of bias
(quality) assessment details (Tables 3–5), the assessment of medicine–test codependency (Table 6),
and the meta-analyses (Figs. 1–3) were not included in the article of Herrera-Gómez et al. [1].
Table 1
Review questions and study eligibility for each of the 4 systematic reviews.
Systematic mapping/systematic review
support for
In-depth systematic review/systematic review
support for
Review
questions
aWhat are the changes in the peripheral blood
immune phenotype that are associated with
COTb?
cWhat effect does the increased frequency of regulatory
cells in the circulation in KTRs and LTRs have on AR/
AAD when using mTORi with/without BELA?
cWhich tolerance-associated blood cells or reg-
ulatory cells increase in the circulation in KTOLs
and LTOLsd?
eWhat effect does the increase in Tregs in the circula-
tion under mTORi-based IS have on AR/AAD in KTRs?
fIs there an increased frequency of Tregs in the
circulationg in KTOLs?
eWhat is the effect of mTORi-based IS on the number of
Tregs in the circulation in KTRs?
fWhat is the effect on AR/AAD that corresponds to an
increased frequency of Tregs in the circulation in KTRs
when using mTORi with/without BELA?
Participants/
population
aPediatric and adult SOTRs. eAdult KTRs.
cAdult KTRs or LTRs. cAdult KTRs or LTRs.
fAdult KTRs. fAdult KTRs.
Intervention
(s)/expo-
sures(s)
aCOT cThe increase in regulatory cells in the circulationg
under mTORi- or mTORi—BELA-based IS.cThe increase in regulatory cells in the
circulationg.
fThe increase in Tregs in the circulationg. emTORi-based IS.
fThe increase in Tregs in the circulationg under mTORi-
or mTORi—BELA-based IS.
Comparators aISDs including KTRs with CR. cDecreased/unchanged numbers of regulatory cells in
the circulationg under CNI- or BELA-based IS.
cDecreased/unchanged numbers of regulatory
cells in the circulationg.
eCNI-based IS
fDecreased/unchanged numbers of Tregs in the
circulationg.
fDecreased/unchanged numbers of Tregs in the
circulationg under CNI- or BELA-based IS.
Outcomes aRegulatory cells that increase in KTOLs, LTOLs
and other tolerant SOTRs.
c,e,fLess AR/AAD events.
c,fCOT. eThe increase in Tregs in the circulation.
Study design Prognostic studiesh RCT
Abbreviations: AR/AAD, acute rejection-associated acute allograft dysfunction; BELA, belatacept; CNI, calcineurin inhibitor;
COT, clinical operational tolerance; CR, chronic rejection; IS, immunosuppression; ISD, immunosuppression dependent reci-
pient; KTOL, tolerant kidney recipient; KTR, kidney transplant recipient; LTOL, tolerant liver recipient; LTR, liver transplant
recipient; mTORi, mammalian Target Of Rapamycin inhibitor; RCT, randomized controlled trial; SOTR, solid organ transplant
recipient; Treg, FoxP3 regulatory T cell.
a One-stage systematic review to support the core systematic mapping (CRD42018084941).
b The state in which recipients exhibits a well-functioning graft and lacks histological signs of rejection after being com-
pletely off all immunosuppression for at least 1 year.
c Core two-stage systematic review constituted of a systematic mapping followed by an in-depth systematic review
(CRD42017057570).
d Increased frequency of Tregs in the circulation are observed in KTOLs and LTOLs, an increase in transitional B cells and
other B cells are seen only in KTOLs, and increased γδ T cells are observed only in LTOLs.
e One-stage systematic review to support the core in-depth systematic review (CRD42018085186).
f In-focus two-stage systematic review of the same design as the core two-stage systematic review
(CRD4201808085019).
g Increased and decreased numbers of cells for each regulatory cell population were deﬁned by the authors of the included
studies according to marker sets for the ﬂow cytometric analysis of these populations.
h Prospective and retrospective comparative cohort studies.
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Table 2
Exclusion criteria.
Overall
 in vivo (animal) and in-vitro studies
 Non-systematic and systematic reviews
Systematic mapping/systematic review support for
Only involving KTRs:
 No analysis of immune cell phenotypes (ﬂow cytometry)
 RCTs
In-depth systematic review/systematic review support for
Only involving KTRs:
 No quantiﬁcation of Tregs (ﬂow cytometry)
 No CNI in control groups
 No measurement of the outcome of AAD
 Comparative and non-comparative cohort (observational) studies
Abbreviations: AAD, acute allograft dysfunction; CNI, calcineurin inhibitor; KTR, kidney
transplant recipient; RCT, randomized controlled trial; Treg, FoxP3 regulatory T cell.
Table 3
Operationalization of the QUIPS tool bias items for assessing risk of bias in prognostic studies.
Potential bias Items to be considered for assessment potential opportu-
nities of bias
Study participationThe study sample adequately repre-
sents the population of interest.
 There is adequate participation in the study by eligible
individuals (kidney recipients).
 The source population or population of interest is adequately
described (demographic and transplantation details).
 The sampling frame and recruitment, period of recruitment,
and place of recruitment (setting and geographic location)
are adequately described.
 Inclusion and exclusion criteria are adequately described.
Study attritionThe study data available (i.e., participants
not lost to follow-up) adequately represents the study
sample.
 Response rate (i.e., proportion of study sample completing
the study and providing outcome data) is adequate.
 Attempts to collect information on participants who drop-
ped out of the study are described, and reasons for loss to
follow-up are provided.
 Participants lost to follow-up are adequately described
Prognostic factor measurement  A clear deﬁnition or description of the prognostic factor
measured (i.e., the changes in the immune phenotype asso-
ciated with operational tolerance) is provided.
 Continuous variables are reported and appropriate (i.e., not
data-dependent) cut-points are used.
 The prognostic factor measurement and methods are ade-
quately valid and reliable.
 An adequate proportion of the study sample has complete
data for the prognostic factor.
 The method and setting of measurement are the same for all
study participants.
The prognostic factor of interest is measured similarly for
all participants.
Outcome measurement  A clear deﬁnition of the outcome of interest (i.e., clinical
operational tolerance after kidney transplantation) is
provided.
 The outcome measures and methods used are adequately
valid and reliable (and may include characteristics, such as
blind measurement and conﬁrmation of outcome with a
valid and reliable test).
 The method and setting of measurement are the same for all
study participants.
The outcome of interest is measured similarly for all
participants.
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Table 3 (continued )
Potential bias Items to be considered for assessment potential opportu-
nities of bias
Confounding measurement and account  All confounders, including treatments, are measured.
 Clear deﬁnitions of the important confounders measured are
provided (e.g., including dose, level, and duration of
exposures).
 The measurement of all important confounders is ade-
quately valid and reliable.
 The method and setting of confounding measurement is the
same for all study participants.
 Appropriate methods are used if imputation is used for
missing confounder data.
 Important potential confounders are accounted for in the
study design (e.g., matching for key variables, stratiﬁcation,
and initial assembly of comparable groups).
 Important potential confounders are accounted for in the
analysis (e.g., appropriate adjustment).
Important potential confounding factors are appro-
priately accounted for
Statistical analysis and reporting  There is sufﬁcient presentation of data to assess the ade-
quacy of the analysis.
 The strategy for model building (i.e., inclusion of variables) is
appropriate and is based on a conceptual framework
or model.
 The selected model is adequate for the design of the study.
 There is no selective reporting of results.
The statistical analysis is appropriate, and all primary
outcomes are reported
Table 4
Assessing risk of bias in eligible prognostic studies eligible using the QUIPS tool.
Studies Study parti-
cipation
Study
attrition
Prognostic factor
measurement
Outcome
measurement
Confounding mea-
surement and account
Statistical analy-
sis and reporting
King's College
London
studyb
Low risk of
bias
Moderate
risk of bias
High risk of bias Low risk of
bias
High risk of bias Low risk of bias
ITN507
(FACTOR)c
Low risk of
bias
Moderate
risk of bias
High risk of bias Low risk of
bias
High risk of bias Low risk of bias
Nantes studyd Low risk of
bias
Moderate
risk of bias
Moderate risk of
bias
Low risk of
bias
High risk of bias Low risk of bias
BMOTSa Low risk of
bias
Low risk of
bias
Moderate risk of
bias
Low risk of
bias
High risk of bias Low risk of bias
Abbreviations: INSERM, Institut National de la Santé Et de la Recherche Médicale; IOT, Indices Of Tolerance; ITN, Immune
Tolerance Network.
a BMOTS, the Brazilian Multicenter Operational Tolerance study.
b IOT consortium study.
c ITN study.
d INSERM study.
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For study selection, deﬁnition of inclusion and exclusion criteria and the full search strategy were
based on the PICOS elements (participants/population, intervention(s)/exposure(s), comparators,
outcomes and study design) [1]. The operationalization of the Quality in Prognosis Studies (QUIPS)
tool was necessary (Table 3) [2,3]. Nevertheless, for the risk of bias assessment, the QUIPS tool and the
Cochrane Collaboration tool [4] were used when appropriate. For the assessment of medicine–test
Table 5
Assessing risk of bias in eligible trials eligible using the Cochrane risk of bias tool.
Trials Random sequence
generation
Allocation
concealment
Blinding of participants and
personnel
Blinding of outcome
assessment
Incomplete out-
come data
Selective
reporting
Other bias
Mario Negri Institute
study
Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Low risk of bias Unclear risk of
bias
Low risk of
bias
Hôpital Edouard Herriot
study
Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Unclear risk of bias Unclear risk of
bias
Unclear risk
of bias
Chandigarh study Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Low risk of bias Unclear risk of
bias
Unclear risk
of bias
University of Foggia
study
Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Unclear risk of bias Unclear risk of
bias
Low risk of
bias
IRCCS Policlinico S.
Matteo studya
Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Low risk of bias Low risk of
bias
Low risk of
bias
BMS-224818 studyb Low risk of bias Low risk of bias Unclear risk of bias Unclear risk of bias Low risk of bias Low risk of
bias
Unclear risk
of bias
Abbreviations: IRCCS, Istituto di ricovero e cura a carattere scientiﬁco.
a Fondazione IRCCS Policlinico San Matteo study.
b Bristol-Myers Squibb study.
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Table 6
Adaptation of the Merlin's tool to assess codependency in the combination of treatment and test.
Information requests Comments
Section 1 – Context
Details about the biomarker, the test and the medicine
1 (O) Current reimbursement arrangements. The medicines and the test are affordable in developed countries,
and are available in more and more developing countries.
2 (T) Test sponsor. Becton, Dickinson and Company (BD).
3 (M) Medicine sponsor. SIR (Pﬁzer: Rapamunes).
BELA (Bristol-Myers-Squibb: Nulojixs)
4 (O) Biomarker. The number of Tregs in the circulation.
5 (T) Proposed test. Quantiﬁcation of circulating Tregs by ﬂow cytometry
6 (O) Medical condition or problem being managed. AR/AADs in KTRs.
7 (O) Clinical management pathways. Monitoring of patients.
Rationale for the codependency
8 (O) Deﬁnition of the biomarker. Increased/decreased Tregs in the circulation.
9 (O) Biological rationale for targeting speciﬁc bio-
marker(s).
Patients with increased Tregs presented less frequent AR/AADs.
10 (O) Other biomarker(s) to assess treatment effect
of the medicine.
None.
11(O) Prevalence of the condition being targeted in
the population that is likely to receive the test.
10%
Proposed impact of codependent technologies on current clinical practice
12 (T) Consistency of the test results over time. Increased Tregs are observed preferentially in KTRs receiving
mTORi with/without BELA.
13 (T) Use of the proposed test with other treatments
and/or for other purposes.
NA
14 (T) Use of the test in the clinical management
pathway.
The test is most likely to be an additional test for managing
patients.
15 (T) Provision of the test. The test is routinely used in hospitals of developed countries.
16 (T) Specimen or sample collection. Peripheral blood.
17 (T) Use of the test for monitoring purposes (if
relevant)
Detection of patients at high risk for AR/AADs.
18(O) Availability of other tests for the biomarker. None.
Section 2 – Clinical evaluation
Direct evidence approach
Section 2a Evidence of prognostic effect of the biomarker
19(O) Prognostic effect of the biomarker. It can be assumed methodologically.
Section 2d Clinical evaluation of the codependent technologies (combined)
20(O) Selection of the direct evidence. Low-level direct evidence is available (retrospective biomarker-
stratiﬁed trials).
21(O) Quality of the direct evidence. The evidence is of adequate quality.
Item numbers are tagged with (T), (M) or (O), which indicate whether the item number is relevant to the test, the medicine or
overlaps both. Abbreviations: AR/AAD, acute rejection-associated acute allograft dysfunction; BELA, belatacept; mTORi,
mammalian Target Of Rapamycin inhibitor; KTR, kidney transplant recipient; SIR, sirolimus.
Fig. 1. Increase in Tregs at 3–6 months post-transplantation. CI, conﬁdence interval; CNI, calcineurin inhibitor; IV, inverse
variance; mTORi, mammalian Target of Rapamycin inhibitor; ST, standard deviation; Tregs, FoxP3 regulatory T cell.
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Fig. 2. Increase in Tregs at 12 months post-transplantation. CI, conﬁdence interval; CNI, calcineurin inhibitor; IV, inverse
variance; mTORi, mammalian Target of Rapamycin inhibitor; ST, standard deviation; Tregs, FoxP3 regulatory T cell.
Fig. 3. Increase in Tregs at 24 months post-transplantation. CI, conﬁdence interval; CNI, calcineurin inhibitor; IV, inverse
variance; mTORi, mammalian Target of Rapamycin inhibitor; ST, standard deviation; Tregs, FoxP3 regulatory T cell.
F. Herrera-Gómez et al. / Data in Brief 21 (2018) 2567–25752574codependency, an adaptation of Merlin's tool included in the guidelines for preparing a submission to
the Pharmaceutical Beneﬁts Advisory Committee (PBAC) from the Department of health of Australia
was used [5,6]. Finally, meta-analytic calculations on continuous outcomes (standardized mean-
difference effect sizes obtained under inverse variance random-effects model) were performed.Acknowledgements
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